Literature DB >> 32354944

Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study.

Evangelos Paraskevaidis1, Antonios Athanasiou2, Maria Paraskevaidi2, Evripidis Bilirakis3, Georgios Galazios4, Emmanuel Kontomanolis4, Konstantinos Dinas5, Aristotelis Loufopoulos5, Maria Nasioutziki5, Ioannis Kalogiannidis6, Apostolos Athanasiadis6, Alexios Papanikolaou5, Anastasia Vatopoulou7, Gregorios Grimbizis7, Dimitrios Tsolakidis7, Alexandros Daponte8, George Valasoulis8, Stella Gritzeli9, Georgios Michail10, Georgios Adonakis10, Minas Paschopoulos11, Orestis Tsonis11, Maria-Eugenia Anaforidou11, Anna Batistatou12, Maria Kyrgiou2.   

Abstract

BACKGROUND: In Greece the population-level impact of HPV vaccination is unknown due to lack of official registries. This study presents in a pragmatic frame the comparison of cervical pathology data between HPV-vaccinated and unvaccinated women referred for colposcopy. PATIENTS AND METHODS: This is an observational prospective cohort study performed in 7 academic Obstetrics and Gynaecology Departments across Greece between 2009-2019. Cases were women that had completed HPV vaccination before coitarche and were referred for colposcopy due to abnormal cytology. For each vaccinated woman an unvaccinated matched control was selected.
RESULTS: A total of 849 women who had been vaccinated before coitarche and 849 unvaccinated controls were recruited. The combination of cytological, colposcopic and molecular findings necessitated treatment in only a single case among vaccinated (0.1%) and in 8.4% among unvaccinated.
CONCLUSION: HPV vaccination at a proper age can markedly reduce development of severe cervical precancers and consequently the need for treatment, as well as their long-term related obstetrical morbidity. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  HPV; vaccination; vaccine

Mesh:

Substances:

Year:  2020        PMID: 32354944      PMCID: PMC7279786          DOI: 10.21873/invivo.11927

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  33 in total

1.  Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes.

Authors:  E Lăără; N E Day; M Hakama
Journal:  Lancet       Date:  1987-05-30       Impact factor: 79.321

2.  Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

Authors:  A Szarewski; W A J Poppe; S R Skinner; C M Wheeler; J Paavonen; P Naud; J Salmeron; S-N Chow; D Apter; H Kitchener; X Castellsagué; J C Teixeira; J Hedrick; U Jaisamrarn; G Limson; S Garland; B Romanowski; F Y Aoki; T F Schwarz; F X Bosch; D M Harper; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

3.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.

Authors:  Laia Bruni; Mireia Diaz; Leslie Barrionuevo-Rosas; Rolando Herrero; Freddie Bray; F Xavier Bosch; Silvia de Sanjosé; Xavier Castellsagué
Journal:  Lancet Glob Health       Date:  2016-07       Impact factor: 26.763

4.  The projected timeframe until cervical cancer elimination in Australia: a modelling study.

Authors:  Michaela T Hall; Kate T Simms; Jie-Bin Lew; Megan A Smith; Julia Ml Brotherton; Marion Saville; Ian H Frazer; Karen Canfell
Journal:  Lancet Public Health       Date:  2018-10-02

5.  Recent Trends in HPV Infection and Type Distribution in Greece.

Authors:  Elena Argyri; Elpida Tsimplaki; Dimitrios Papatheodorou; Dimitra Daskalopoulou; Efstathia Panotopoulou
Journal:  Anticancer Res       Date:  2018-05       Impact factor: 2.480

Review 6.  Epidemiology and natural history of human papillomavirus infections in the female genital tract.

Authors:  Kevin A Ault
Journal:  Infect Dis Obstet Gynecol       Date:  2006

Review 7.  Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis.

Authors:  Maria Kyrgiou; Anita Mitra; Marc Arbyn; Sofia Melina Stasinou; Pierre Martin-Hirsch; Phillip Bennett; Evangelos Paraskevaidis
Journal:  BMJ       Date:  2014-10-28

8.  Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Authors:  Tim Palmer; Lynn Wallace; Kevin G Pollock; Kate Cuschieri; Chris Robertson; Kim Kavanagh; Margaret Cruickshank
Journal:  BMJ       Date:  2019-04-03

9.  Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities.

Authors:  Emmanuela Gakidou; Stella Nordhagen; Ziad Obermeyer
Journal:  PLoS Med       Date:  2008-06-17       Impact factor: 11.069

10.  Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature.

Authors:  I Kalliala; A Athanasiou; A A Veroniki; G Salanti; O Efthimiou; N Raftis; S Bowden; M Paraskevaidi; K Aro; M Arbyn; P Bennett; P Nieminen; E Paraskevaidis; M Kyrgiou
Journal:  Ann Oncol       Date:  2020-01-03       Impact factor: 32.976

View more
  1 in total

1.  Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivity: Prolonged Follow Up Study.

Authors:  George Valasoulis; Georgios Michail; Abraham Pouliakis; Georgios Androutsopoulos; Ioannis G Panayiotides; Maria Kyrgiou; Alexandros Daponte; Evangelos Paraskevaidis
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.